A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion

Future Oncol. 2022 Feb;18(6):669-677. doi: 10.2217/fon-2021-1035. Epub 2022 Jan 26.

Abstract

Aim: To investigate the efficacy, safety and optimal dosage of bevacizumab in non-squamous, non-small-cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE). Methods: 20 patients were enrolled and received intrapleural injection of bevacizumab (group A: 2.5 mg/kg d1, d8; group B: 5 mg/kg d1, d8; group C: 7.5 mg/kg d1, d8). Results: The objective response rate (ORR) of MPE was 50%. The median progression-free survival (PFS) of MPE was 7.0 months (95% CI 4.9-9.2). The ORR and PFS of MPE from group B were better than those of group A and group C. The most common adverse events (AEs) were hypertension (15%) and anemia (15%). Conclusion: Bevacizumab has certain efficacy in non-squamous NSCLC patients with MPE. Clinical Trial Registration: NCT02942043 (ClinicalTrials.gov).

Keywords: bevacizumab; malignant pleural effusion; non-small-cell lung cancer; phase II.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects
  • Antineoplastic Agents, Immunological / administration & dosage*
  • Antineoplastic Agents, Immunological / adverse effects
  • Bevacizumab / administration & dosage*
  • Bevacizumab / adverse effects
  • Carcinoma, Non-Small-Cell Lung / complications*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Female
  • Humans
  • Lung Neoplasms / complications*
  • Lung Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Pleural Effusion, Malignant / drug therapy*
  • Pleural Effusion, Malignant / etiology
  • Progression-Free Survival
  • Prospective Studies

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Immunological
  • Bevacizumab

Associated data

  • ClinicalTrials.gov/NCT02942043